COPENHAGEN (Reuters) -Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people ...

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. In the obesity drug universe, the rise of GLP-1 ...

As part of the deal, the companies will work together to develop Zealand’s amylin analog as a foundational therapy for weight management as well as Roche’s petrelintide and CT-388, which are GLP-1/GIP ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight ...

December 10, 2024 Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its ...

The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes. The ZUPREME-2 trial is designed to evaluate three ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to ...